Trialtrove is the world’s most comprehensive source of pharmaceutical clinical trial data and intelligence from Citeline.
How it helps
Don’t waste time combing through onerous trials reports to get the information you need. Trialtrove analysts do the information gathering for you.
How it works
Trialtrove uses over 40,000 sources to bring you the most comprehensive trial intelligence imaginable.
We extract the protocol details that matter, including objectives, endpoints, and inclusion/exclusion criteria. We also add industry-relevant search terms such as our proprietary patient segments, trial outcomes and biomarker tags, so that you can quickly filter to get to the up-to-date information you need.
Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet...
Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.
A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.
Patient-centric trials have been growing for years. Backed by data from Citeline’s Trialtrove, our latest infographic reveals the trends, the sponsors, and the impact on outcomes around Phase I, II, and III industry-sponsored, patient-centric trials.
See last year’s clinical trial activity through the eyes of our expert analysts and get a better sense of where the industry is headed. This new whitepaper is the annual analysis of Phase I-III clinical trials, from Citeline’s Trialtrove, and reveals the priorities and strategies of the biopharma industry.
Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.
The landscape of trials initiated by industry sponsors is one metric that informs about the R&D health of the biopharma industry. Looking specifically at trial completions adds a layer of granularity to the trials landscape and provides valuable perspective on how well industry pipelines are faring. As Informa Pharma has done for the past four years, we report the results from our analysis of the landscape of clinical trials completed during 2018.
Citeline, Sitetrove, Trialtrove, Pharmaprojects
Citeline is the industry’s most comprehensive, reliable and up-to-date global clinical trial intelligence suite, designed to help you save time and money by enrolling patients faster. Our team of more than 250 industry experts transform data into knowledge, integrating robust drug, trial, investigator, and site intelligence.
For a detailed look at the statistics and trends surrounding clinical trials initiated in 2017, we invite you to download 2017 Clinical Trials Roundup: The Evolution Continues. Using a wealth of trial data from Trialtrove, this information-packed white paper provides a detailed analysis of Phase I–III clinical trials that were initiated last year.
Topic Clinical trials
As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.
Topic Clinical trials
Explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.
Sepsis is a life-threatening illness culminating in multi-organ dysfunction paired with a systemic inflammatory response. The disease burden is considerable: it is the single most expensive condition treated in hospitals, with annual costs in the US projected at nearly $24bn.
Laura specializes in
+34 year(s) experience
Judy specializes in
+32 year(s) experience
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: